← Back to headlines
Inventiva Reaches Final Patient Visit in NATiV3 Phase 3 MASH Trial
The pharmaceutical firm completed enrollment for its phase 3 clinical trial evaluating lanifibranor for metabolic dysfunction-associated steatohepatitis.
2 Sept, 20:05 — 2 Sept, 20:05
